Antisense Inhibition of Apolipoprotein C-III in Patients with HypertriglyceridemiaDaniel Gaudet, John J.P. Kastelein, Karine Tremblay et al.|New England Journal of Medicine|2015Cited by 526
Targeting APOC3 in the Familial Chylomicronemia SyndromeDaniel Gaudet, Joseph L. Witztum, Steven G. Hughes et al.|New England Journal of Medicine|2014Cited by 492
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemiaDaniel Gaudet, Eunju Hurh, Louis O’Dea et al.|European Heart Journal|2020Cited by 276